Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.62 |
| ▸ | HPGD | P15428 | 3/20 | 0.59 |
| ▸ | NPC1 | O15118 | 2/20 | 0.59 |
| ▸ | RAB9A | P51151 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | CA1 | P00915 | 4/20 | 0.55 |
| ▸ | CA2 | P00918 | 4/20 | 0.55 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4275036 | 0.89 | S1PR1 (0.55) | POLBHPGDNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4265384 | 0.88 | CA1 (0.55) | POLBHPGDNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL7768642 | 0.88 | CA1 (0.55) | POLBHPGDNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL8772754 | 0.88 | CA1 (0.55) | POLBHPGDNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1197762 | 0.88 | CA1 (0.55) | POLBHPGDNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL7511976 | 0.85 | ICMT (0.54) | POLBCA1CA2TRPV1S1PR1 | |
| SCHEMBL486896 | 0.84 | CA1 (0.55) | POLBHPGDNPC1RAB9AALDH1A1 | |
| SCHEMBL9312715 | 0.81 | POLB (0.84) | POLBHPGDNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2619349 | 0.80 | POLB (0.76) | POLBHPGDNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2019464 | 0.80 | POLB (0.70) | POLBHPGDNPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 312 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137621-A1 | ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS | DIASOME PHARMACEUTICALS INC (US) | 2026-05-21 | — | — | US | claimed |
| US-20250288521-A1 | ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS | DIASOME PHARMACEUTICALS INC (US) | 2025-09-18 | — | — | US | claimed |
| WO-2022018689-A1 | MESH MATERIALS FOR CONTROLLED RELEASE OF ANTIVIRALS, METHOD AND USE | UNIVERSIDADE FEDERAL DE MINAS GERAIS (BR) | 2022-01-27 | — | — | WO | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-8268352-B2 | Modified release composition for highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-18 | — | — | US | claimed |
| US-8263125-B2 | Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-11 | — | — | US | claimed |
| US-20110135725-A1 | Lipid Construct for Delivery of Insulin to a Mammal | SDG, INC. (US) | 2011-06-09 | — | — | US | claimed |
| WO-2011022396-A1 | LIPID CONSTRUCT FOR DELIVERY OF INSULIN TO A MAMMAL | SDG, INC. (US) | 2011-02-24 | — | — | WO | claimed |
| US-7871641-B2 | Hepatocyte-targeting vehicle for delivery of glargine insulin to a mammal | SDG, INC. (US) | 2011-01-18 | — | — | US | claimed |
| US-7858116-B2 | Hepatocyte delivery vehicle for delivery of a combination of recombinant human regular insulin and recombinant human insulin isophane to a mammal | SDG, INC. (US) | 2010-12-28 | — | — | US | claimed |
| WO-2006127361-A2 | LIPID CONSTRUCT FOR DELIVERY OF INSULIN TO A MAMMAL | SDG, INC. (US) | 2006-11-30 | — | — | WO | claimed |
| US-20060222698-A1 | Hepatocyte delivery vehicle for delivery of glargine insulin to a mammal | SDG, INC. | 2006-10-05 | — | — | US | claimed |
| US-20060222697-A1 | Hepatocyte delivery vehicle for delivery of a combination of recombinant human regular insulin and recombinant human insulin isophane to a mammal | SDG, INC. | 2006-10-05 | — | — | US | claimed |
| US-20060024365-A1 | Novel dosage form | VAYA NAVIN | 2006-02-02 | — | — | US | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| CN-1261791-A | Targeted liposomal constructs for diagnostic and therapeutic uses | SDG INC (US) | 2000-08-02 | — | — | CN | claimed |
| EP-0999855-A1 | POLYMER BASED PHARMACEUTICAL COMPOSITIONS FOR TARGETED DELIVERY OF BIOLOGICALLY ACTIVE AGENTS | SDG, Inc. (US) | 2000-05-17 | — | — | EP | claimed |
| US-6063400-A | CARRIER; DIAGNOSTIC OR THERAPEUTIC AGENT AND SEQUESTERING AGENT | SDG, INC. (US) | 2000-05-16 | — | — | US | claimed |
| WO-1999004824-A1 | POLYMER BASED PHARMACEUTICAL COMPOSITIONS FOR TARGETED DELIVERY OF BIOLOGICALLY ACTIVE AGENTS | SDG, INC. (US) | 1999-02-04 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250288521-A1 | ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS | FABP2, FABP1, FABP6 | POLB 4282/4885HPGD 1531/4885NPC1 228/4885 |
| US-20260137621-A1 | ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS | FABP2, FABP1, SGMS2 | POLB 4659/4885HPGD 2154/4885NPC1 23/4885 |
| US-20060222698-A1 | Hepatocyte delivery vehicle for delivery of glargine insulin to a mammal | INSR, GPR119, GCG | POLB 3957/4885HPGD 1849/4885NPC1 234/4885 |
| US-20110135725-A1 | Lipid Construct for Delivery of Insulin to a Mammal | INSR, IAPP, GPR119 | POLB 4755/4885HPGD 3818/4885NPC1 75/4885 |
| US-20060222697-A1 | Hepatocyte delivery vehicle for delivery of a combination of recombinant human regular insulin and recombinant human insulin isophane to a mammal | INSR, INSRR, IAPP | POLB 4685/4885HPGD 2177/4885NPC1 347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.